Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abatacept for the Treatment of GLILD in CVID
NCT04925375Phase 2Recruiting
- Sponsor
- Cincinnati Children's Hospital Medical Center
- Start
- Jul 2021
- Primary completion
- Jul 2028
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of abatacept in Granulomatous-lymphocytic interstitial lung disease (GLILD), common variable immunodeficiency (CVID), sponsored by Cincinnati Children's Hospital Medical Center. Started Jul 2021; status: recruiting.
02
Drugs
abatacept
03
Conditions
Granulomatous-lymphocytic interstitial lung disease (GLILD)common variable immunodeficiency (CVID)
Beyond the preview
Go deeper on NCT04925375.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04925375.